Hemangioblastoma Overview

Save information for later
Sign Up

Learn About Hemangioblastoma

View Main Condition: Brain Tumor

What is the definition of Hemangioblastoma?
A Hemangioblastoma is a benign, highly vascular tumor that can occur in the brain, spinal cord, and retina (the light-sensitive tissue that lines the back of the eye). This tumor accounts for about 2% of brain tumors. As it enlarges, it presses on the brain and can cause neurological symptoms, such as headaches, weakness, sensory loss, balance and coordination problems, and/or hydrocephalus (a buildup of spinal fluid in the brain). Most Hemangioblastomas occur sporadically. However, some people develop Hemangioblastomas as part of a genetic syndrome called von Hippel-Lindau syndrome. These people usually develop multiple tumors within the brain and spinal cord over their lifetime.
What are the alternative names for Hemangioblastoma?
  • Hemangioblastoma
Who are the top Hemangioblastoma Local Doctors?
Elite in Hemangioblastoma
Dr. Russell R. Lonser
Neurosurgery
Elite in Hemangioblastoma
Dr. Russell R. Lonser
Neurosurgery

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Russell Lonser is a Neurosurgery provider in Columbus, Ohio. Dr. Lonser is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. His top areas of expertise are Hemangioblastoma, Von Hippel-Lindau (VHL) Syndrome, Hemangioma, Awake Craniotomy, and Craniectomy. Dr. Lonser is currently accepting new patients.

Elite in Hemangioblastoma
Dr. Eric A. Jonasch
Oncology
Elite in Hemangioblastoma
Dr. Eric A. Jonasch
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jonasch is an Oncologist in Houston, Texas. Dr. Jonasch is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Hemangioblastoma, Chromophobe Renal Cell Carcinoma, Hypothalamic Hamartomas, and Nephrectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hemangioblastoma
Dr. Othon Iliopoulos
Oncology
Elite in Hemangioblastoma
Dr. Othon Iliopoulos
Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Othon Iliopoulos is an Oncologist in Boston, Massachusetts. Dr. Iliopoulos is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. His top areas of expertise are Hemangioblastoma, Hypothalamic Hamartomas, Renal Cell Carcinoma (RCC), and Koolen De Vries Syndrome. Dr. Iliopoulos is currently accepting new patients.

View All Doctors
What are the latest Hemangioblastoma Clinical Trials?
The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan
The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Enrollment Status: Recruiting
Publish Date: January 03, 2025
Intervention Type: Other

Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center